

## ■ EDITORIAL

# In-hospital outcomes in COVID-19 patients: Did we learn something?

Marijana Tadic<sup>1</sup>, Cesare Cuspidi<sup>2</sup><sup>1</sup>Klinik für Innere Medizin II, Universitätsklinikum Ulm, Germany<sup>2</sup>Department of Medicine and Surgery, University of Milano-Bicocca, and Milano Istituto Auxologico Italiano, IRCCS, Milano, Italy

## Related article

by Terlecki et al.

see p. 773

### Correspondence to:

Marijana Tadic, MD, PhD,  
Klinik für Innere Medizin II,  
Universitätsklinikum Ulm,  
Albert-Einstein Allee 23,  
89081, Ulm, Germany,  
phone: +49 17 632 360 011  
e-mail: marijana\_tadic@  
hotmail.comCopyright by the Author(s),  
2021Kardiologia Pol. 2021;  
79 (7–8): 730–732;  
DOI: 10.33963/KPa2021.0027

### Received:

May 23, 2021

### Revision accepted:

May 29, 2021

### Published online:

May 31, 2021

Coronavirus disease 2019 (COVID-19) has fundamentally changed everything since December 2019 when World Health Organization (WHO) confirmed this virus for the first time. A novel coronavirus, SARS-CoV-2, spread extremely fast around the globe and WHO claimed a global pandemic in March 2020.

One of the most important questions that was raised at the beginning of the pandemic has been risk factors that are associated with SARS-CoV-2 infection, worse clinical manifestation of COVID-19 and adverse outcome. The first results indicated that advanced age, male sex, previous cardiovascular, and respiratory diseases were risk factors for infection and worse clinical outcomes (treatment in intensive care units, intubation, and in-hospital mortality) [1]. However, these studies were usually performed in a single center, included a limited number of patients of only one race, provided a relatively short follow-up with scarce information about confounding factors that might interfere the final results [1]. Due to the lack of data about potential confounding factors and misinterpretation of obtained results, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) were declared as potentially dangerous in COVID-19 patients [2], which raised many questions. Fortunately, extensive sets data showed that ACEIs and ARBs were not associated with higher risk of infection, intubation or mortality in COVID-19 patients [3].

In this issue of *Kardiologia Pol*, Terlecki et al. [4] reported data about the relationship between cardiovascular (CV) diseases, CV therapy, and in-hospital mortality in the large cohort of

COVID-19 patients from a single-center registry in Poland. The authors confirmed existing evidence that advanced age, male sex, diabetes mellitus, and pre-existing heart failure were the major predictors of adverse outcomes in these patients. The most innovative part of this investigation refers to the protective effect of CV medications, including ACEI/ARB, beta-blockers, statins, and antiplatelet agents, in COVID-19 patients [4].

The most prevalent CV diseases in this study were arterial hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, heart failure, atrial fibrillation, and stroke [4]. Age over 65 years, male sex, pre-existing diabetes mellitus, and heart failure were independent predictors of in-hospital mortality, whereas treatment with ACEIs/ARBs, beta-blockers (BBs), statins, or antiplatelet therapy was related with lower in-hospital mortality [4]. Stroke also showed a borderline significance as an independent predictor of in-hospital mortality ( $P = 0.07$ ).

The effect of ACEI/ARB on outcome in COVID-19 patients has not been completely understood because results still vary in different studies depending of which outcome has been investigated and which parameters were used for adjustment in statistical models [5]. In a large cohort of 824 650 patients with hypertension from a US integrated healthcare system it was found that ACEI/ARB use did not increase the risk of COVID-19 [5]. Interestingly, ACEI use was associated with decreased risk of COVID-19 among hypertensive patients older than 85 years. A recently published meta-analysis revealed that the use of ACEI/ARB was independently associated with the reduction

of severe adverse events and mortality in all patients, as well as in a subgroup of hypertensive patients [6]. Ren et al. [7] included 2,100,587 participants in a meta-analysis and revealed no association between prior usage of antihypertensive medications including ACEIs/ARBs, calcium channel blockers (CCBs), BBs, or diuretics and the risk and severity of COVID-19. Furthermore, the severity and mortality were significantly lower in hypertensive patients with prior usage of ACEIs/ARBs [7]. The beneficial effect of statins on mortality in COVID-19 has been also recently reported [8]. However, there are also large studies that showed no evidence that antihypertensive therapy was associated with increased risk of COVID-19 or mortality [9]. ACEI/ARBs, CCBs and diuretics were associated with lower risk of COVID-19, whereas only BBs were associated with higher risk of COVID-19 [9]. Another investigation showed that BBs were independently associated with better outcomes and less severe course of disease, whereas CCBs correlated with poor outcomes (ICU admission and mortality) [10]. ACEI/ARBs and diuretics were not associated with any outcomes [10].

The effect of antithrombotic therapy, both antiplatelet and anticoagulant treatment, on outcomes in COVID-19 has not been established yet. Russo et al. [11] have recently reported that such a type of therapy was not associated with better outcome in patients with severe COVID-19 with acute respiratory syndrome at presentation. A meta-analysis that included 5970 COVID-19 patients confirmed that antiplatelet therapy did not decrease mortality in these patients [12]. On the other hand, the study that included almost 2000 COVID-19 patients reported positive effect of aspirin on in-hospital mortality [13].

The major limitation of available studies is the lack of information about the control of the primary disease (hypertension, heart failure, coronary artery disease, atrial fibrillation) and its control before and during COVID-19. The recent study demonstrated that patients with stage 1 uncontrolled blood pressure (140/90–159/99 mm Hg) had lower risk of COVID-19 death compared with those with well-controlled blood pressure, who were older, had more comorbidities, and had been diagnosed with hypertension for a longer period of time [14]. However, in the study in which patients are of similar age, prevalence of comorbidities and duration of hypertension, one would expect that control of main comorbidities in COVID-19 patients, such as hypertension, heart failure, diabetes, atrial fibrillation or coronary artery disease, have an essential role in the prediction of outcome in COVID-19 patients. The study by Terlecki et al. [4] did not include other medications, such as diuretics, antidiabetics, and anticoagulants in the final multivariable analysis. Even though data about body mass index (BMI) and creatinine level were provided, the authors did not consider the effect of obesity or renal dysfunction on the outcomes in this population. The same is true with the potential effect of pulmonary diseases (asthma and

chronic obstructive pulmonary disease [COPD]) that was not examined in the statistical model. Data about specific or unspecific therapy used for treatment of COVID-19, aside from oxygen therapy, were not provided, and it might be essential in prediction of adverse outcomes.

The diversity of published results about the impact of CV diseases and therapy on outcome in COVID-19 patients reveals the lack of understanding of mechanisms that would potentially explain the relationship (positive or negative) between CV drugs and COVID-19. Furthermore, the detailed analysis of all potential risk factors on severity of COVID-19 and its outcome, with longer follow-up would be very much appreciated.

## Article information

**Conflict of interest:** None declared.

**Open access:** This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at [kardiologiapolska@ptkardio.pl](mailto:kardiologiapolska@ptkardio.pl).

**How to cite:** Tadic M, Cuspidi C. In-hospital outcome in COVID-19 patients: Did we learn something? *Kardiol Pol.* 2021; 79(7–8): 730–732, doi: 10.33963/KP.a2021.0027.

## REFERENCES

1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* 2020; 180(7): 934–943, doi: 10.1001/jamainternmed.2020.0994, indexed in Pubmed: 32167524.
2. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* 2020; 5(7): 811–818, doi: 10.1001/jamacardio.2020.1017, indexed in Pubmed: 32219356.
3. Savarese G, Benson L, Sundström J, et al. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. *Eur J Heart Fail.* 2021; 23(3): 476–485, doi: 10.1002/ejhf.2060, indexed in Pubmed: 33222412.
4. Terlecki M, Wojciechowska W, Klocek M, et al. Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland. *Kardiol Pol.* 2021; 79(7–8): 773–780, doi: 10.33963/KP.15990, indexed in Pubmed: 33926173.
5. An J, Wei R, Zhou H, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system. *J Am Heart Assoc.* 2021; 10(3): e019669, doi: 10.1161/JAHA.120.019669, indexed in Pubmed: 33307964.
6. Baral R, Tsampasian V, Debski M, et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. *JAMA Netw Open.* 2021; 4(3): e213594, doi: 10.1001/jamanetworkopen.2021.3594, indexed in Pubmed: 33787911.
7. Ren L, Yu S, Xu W, et al. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis. *J Cardiol.* 2021; 77(5): 482–491, doi: 10.1016/j.jjcc.2020.10.015, indexed in Pubmed: 33168337.
8. Lee HY, Ahn J, Park J, et al. Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases. Beneficial effect of statins in covid-19-related outcomes-brief report: a national population-based

- cohort study. *Arterioscler Thromb Vasc Biol.* 2021; 41(3): e175–e182, doi: [10.1161/ATVBAHA.120.315551](https://doi.org/10.1161/ATVBAHA.120.315551), indexed in Pubmed: [33535790](https://pubmed.ncbi.nlm.nih.gov/33535790/).
9. Rezel-Potts E, Douiri A, Chowienzyk PJ, et al. Antihypertensive medications and COVID-19 diagnosis and mortality: population-based case-control analysis in the United Kingdom. *Br J Clin Pharmacol.* 2021 [Epub ahead of print], doi: [10.1111/bcp.14873](https://doi.org/10.1111/bcp.14873), indexed in Pubmed: [33908074](https://pubmed.ncbi.nlm.nih.gov/33908074/).
  10. Pinto-Sietsma SJ, Flossdorf M, Buchholz VR, et al. Antihypertensive drugs in COVID-19 infection. *Eur Heart J Cardiovasc Pharmacother.* 2020; 6(6): 415–416, doi: [10.1093/ehjcvp/pvaa058](https://doi.org/10.1093/ehjcvp/pvaa058), indexed in Pubmed: [32501477](https://pubmed.ncbi.nlm.nih.gov/32501477/).
  11. Russo V, Di Maio M, Attena E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. *Pharmacol Res.* 2020; 159: 104965, doi: [10.1016/j.phrs.2020.104965](https://doi.org/10.1016/j.phrs.2020.104965), indexed in Pubmed: [32474087](https://pubmed.ncbi.nlm.nih.gov/32474087/).
  12. Wang Y, Ao G, Nasr B, et al. Effect of antiplatelet treatments on patients with COVID-19 infection: a systematic review and meta-analysis. *Am J Emerg Med.* 2021; 43: 27–30, doi: [10.1016/j.ajem.2021.01.016](https://doi.org/10.1016/j.ajem.2021.01.016), indexed in Pubmed: [33485124](https://pubmed.ncbi.nlm.nih.gov/33485124/).
  13. Meizlish ML, Goshua G, Liu Y, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. *Am J Hematol.* 2021; 96(4): 471–479, doi: [10.1101/2021.01.12.21249577](https://doi.org/10.1101/2021.01.12.21249577), indexed in Pubmed: [33469595](https://pubmed.ncbi.nlm.nih.gov/33469595/).
  14. Sheppard JP, Nicholson BD, Lee J, et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: an observational cohort study. *Hypertension.* 2021; 77(3): 846–855, doi: [10.1161/HYPERTENSIONA-HA.120.16472](https://doi.org/10.1161/HYPERTENSIONA-HA.120.16472), indexed in Pubmed: [33325240](https://pubmed.ncbi.nlm.nih.gov/33325240/).